Artículo | 2024 | A global action agenda for turning the tide on fatty liver disease | HEPATOLOGY |
Letter | 2024 | Letter to the Editor: Serum Identification of At-Risk MASH: The Metabolomics-Advanced Steatohepatitis Fibrosis Score (MASEF) | HEPATOLOGY |
Letter | 2024 | Letter to the Editor: Serum Identification of At-Risk MASH: The Metabolomics-Advanced Steatohepatitis Fibrosis Score (MASEF) | HEPATOLOGY |
Editorial | 2024 | Looking for the best algorithm in the diabetes population for advanced fibrosis detection: the best is the enemy of the good | HEPATOLOGY |
Artículo | 2024 | Pre-emptive TIPS in high-risk acute variceal bleeding. An updated and revised individual patient data meta-analysis | HEPATOLOGY |
Artículo | 2024 | Predictive factors for decompensating events in cirrhotic patients with primary biliary cholangitis under different lines of therapy | HEPATOLOGY |
Artículo | 2024 | Recent outcomes of liver transplantation for Budd-Chiari syndrome: A study of the European Liver Transplant Registry (ELTR) and affiliated centers | HEPATOLOGY |
Artículo | 2024 | Risk of liver-related events in metabolic dysfunction-associated steatohepatitis (MASH) patients with fibrosis: A comparative analysis of various risk stratification criteria. | HEPATOLOGY |
Artículo | 2024 | Serum identification of at-risk MASH: The metabolomics-advanced steatohepatitis fibrosis score (MASEF) | HEPATOLOGY |
Artículo | 2023 | A multisociety Delphi consensus statement on new fatty liver disease nomenclature | HEPATOLOGY |
Resumen congreso | 2023 | At- risk nash identification using an algorithm that combines fib-4+masef ( metabolomicsadvanced steatohepatitis fibrosis score) | HEPATOLOGY |
Resumen congreso | 2023 | Clinical utility of liver and spleen elastography in the management of patients living with liver disease | HEPATOLOGY |
Resumen congreso | 2023 | Development and validation of a new imaging biomarker combining demili and mre to identify at risk nonalcoholic steatohepatitis ( at- risk nash) patients | HEPATOLOGY |
Resumen congreso | 2023 | EFFECTIVENESS AND SAFETY OF SECOND-LINE THERAPY IN PRIMARY BILIARY CHOLANGITIS (PBC): A PROSPECTIVE MULTICENTER REAL-WORLD COHORT | HEPATOLOGY |
Resumen congreso | 2023 | Efficacy and safety of efinopegdutide in hispanic patients with nonalcoholic fatty liver disease: results from an active comparator-controlled study | HEPATOLOGY |
Resumen congreso | 2023 | Efficacy of efinopegdutide in nonalcoholic fatty liver disease: subgroup analyses from an active-comparator-controlled study | HEPATOLOGY |
Resumen congreso | 2023 | Hepcityfree/ spanish alliance for viral hepatitis elimination: the commitment of spanish cities for hepatitis c elimination | HEPATOLOGY |
Resumen congreso | 2023 | HISTOLOGICAL CLASSIFICATIONS AND PREDICTION OF LIVER- RELATED EVENTS : RESULTS FROM THE MULTICENTRIC, EUROPEAN, HEPATIC OUTCOMES AND SURVIVAL FATTY LIVER REGISTRY ( HOTSURFR) STUDY | HEPATOLOGY |
Resumen congreso | 2023 | Identification of new serological biomarkers for the detection of significant fibrosis | HEPATOLOGY |
Resumen congreso | 2023 | IMPACT OF COMORBIDITIES ON LIVER TRANSPLANTATION: A PROSPECTIVE AND MULTICENTRIC ANALYSIS | HEPATOLOGY |
Resumen congreso | 2023 | Longitudinal study of nafld progression using paired biopsies in a well-characterised european cohort | HEPATOLOGY |
Artículo | 2023 | Machine learning algorithm improves the detection of NASH (NAS-based) and at-risk NASH: a development and validation study | HEPATOLOGY |
Resumen congreso | 2023 | Non-alcoholic fatty liver disease (nafld) is associated with significant impairment of work productivity: data from the global nash registry™ | HEPATOLOGY |
Resumen congreso | 2023 | NOVEL ARTIFICIAL INTELLIGENCE-ASSISTED DIGITAL PATHOLOGY QUANTITATIVE IMAGE ANALYSIS PREDICTS THE OCCURRENCE OF LIVER-RELATED CLINICAL EVENTS IN THE MULTICENTRIC, EUROPEAN, HEPATIC OUTCOMES AND SURVIVAL FATTY LIVER REGISTRY (HOTSURFR) STUDY | HEPATOLOGY |
Resumen congreso | 2023 | Potent and polyfunctional hepatitis b core (hbc)/surface (hbs)-specific cd8+and cd4+t cell responses observed in adults with chronic hepatitis b (chb) following targeted immunotherapy consisting of viral vectors in heterologous prime-boost regimen and adjuvanted hbc/hbs proteins: results on step b cohort of a phase i/ii trial | HEPATOLOGY |
Artículo | 2023 | Predicting liver-related events in NAFLD: A predictive model | HEPATOLOGY |
Resumen congreso | 2023 | PREDICTION OF BIOCHEMICAL RESPONSE IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS TREATED WITH OBETICHOLIC ACID: DERIVATION AND EXTERNAL VALIDATION OF THE OCA RESPONSE SCORE (ORS) | HEPATOLOGY |
Artículo | 2023 | Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study | HEPATOLOGY |
Resumen congreso | 2023 | Serial vibration controlled transient elastography (vcte)-based agile scores predict liver-related events in nonalcoholic fatty liver disease (nafld) - a multicenter cohort study of 16,603 patients | HEPATOLOGY |
Resumen congreso | 2023 | Stigma is a predictor of impairment of health related quality of life among patients with nafld | HEPATOLOGY |
Resumen congreso | 2023 | The global survey of disease burden and stigma among patients with nafld and their healthcare providers | HEPATOLOGY |
Resumen congreso | 2023 | Understanding barriers in non-alcoholic liver disease (nafld) management: insights from a multi-disciplinary survey of physicians in europe (barriers-nafld) | HEPATOLOGY |
Resumen congreso | 2023 | What patients with nonalcoholic fatty liver disease should we treat with pharmacological agents? | HEPATOLOGY |
Artículo | 2022 | Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis | HEPATOLOGY |
Resumen congreso | 2022 | Clinical and Patient-Reported Outcome (PRO) profile of patients with Hepatitis B Viral (HBV) infection from the Global Liver Registry (TM) (GLR (TM)) | HEPATOLOGY |
Resumen congreso | 2022 | Depression and emotional distress in patients with Chronic Liver Disease (CLD): data from the Global Liver Registry (TM) (GLR (TM)) | HEPATOLOGY |
Resumen congreso | 2022 | DIFFERENTIAL BIOMARKERS EXPRESSION IN THE TUMOR MICROENVIRONMENT OF RESECTED HEPATOCELLULAR CARCINOMA | HEPATOLOGY |
Resumen congreso | 2022 | EpCAM+CD133+Microvesicles: novel biomarker in NAFLD | HEPATOLOGY |
Resumen congreso | 2022 | Glutaminolysis and steatosis to steatohepatitis transition: role of glutaminase | HEPATOLOGY |
Resumen congreso | 2022 | Impact of genes related to metabolic associated fatty liver disease (MAFLD) in response to hypocaloric dietary intervention: nutrigenomic analysis | HEPATOLOGY |
Resumen congreso | 2022 | In cirrhotic patients with portal hypertension related bleeding. (B/PHT), the use of tamponade not followed by tips is an independent predictor of long-term (6-month and 1-year) mortality | HEPATOLOGY |
Artículo | 2022 | Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles | HEPATOLOGY |
Resumen congreso | 2022 | Real-world evidence on non-invasive tests and associated cut-offs used to assess fibrosis in routine clinical practice | HEPATOLOGY |
Resumen congreso | 2022 | Rescue tips (Rtips) must be considered as soon as a tamponade is used: results from two international multicenter cohorts of 3019 patients with portal hypertension (PTH)-related bleeding. | HEPATOLOGY |
Artículo | 2022 | Up-regulation of thioesterase superfamily member 2 in skeletal muscle promotes hepatic steatosis and insulin resistance in mice | HEPATOLOGY |
Artículo | 2021 | A machine learning approach enables quantitative measurement of liver histology and disease monitoring in NASH | HEPATOLOGY |
Artículo | 2021 | ABIDE: An Accurate Predictive Model of Liver Decompensation in Patients With Nonalcoholic Fatty Liver-Related Cirrhosis | HEPATOLOGY |
Resumen congreso | 2021 | LOW HYPOCALORIC MEDITERRANEAN DIET VERSUS STANDARD DIET IN BIOPSY PROVEN NAFLD PATIENTS | HEPATOLOGY |
Resumen congreso | 2020 | A global review of national NAFLD and NASH policies | HEPATOLOGY |
Resumen congreso | 2020 | A retrospective registry review of chronic viral hepatitis patients and associated risk factors of late presentation to care in Spain, a country with unrestricted treatment access | HEPATOLOGY |
Resumen congreso | 2020 | A systematic review of comprehensive models of care for NAFLD and NASH | HEPATOLOGY |
Resumen congreso | 2020 | Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis (NASH) | HEPATOLOGY |
Resumen congreso | 2020 | Clinical and patient-reported outcomes data of non-alcoholic fatty liver disease: longitudinal data from the global NASH registry (TM) | HEPATOLOGY |
Resumen congreso | 2020 | FIB-4 and fibroscan can identify patients with nonalcoholic fatty liver disease who are at risk of liver-related events: results of a longitudinal analysis with comparison with liver biopsy | HEPATOLOGY |
Resumen congreso | 2020 | Patient-reported outcomes in patients with chronic hepatitis C: data from the global liver registry (TM) | HEPATOLOGY |
Artículo | 2020 | qFIBS: an automated technique for quantitative evaluation of fibrosis, inflammation, ballooning, and steatosis in patients with nonalcoholic steatohepatitis | HEPATOLOGY |
Resumen congreso | 2020 | Selection based on SAF activity score, not NASH CRN NAFLD activity score, leads to selection of a patient cohort with more severe NASH with more advanced fibrosis: experience from the native phase 2b study of the panppar agonist lanifibranor | HEPATOLOGY |
Resumen congreso | 2020 | Significant knowledge gap about non-alcoholic fatty liver disease (NAFLD) in real-world practices: a global survey of hepatologists, gastroenterologists, endocrinologists and primary care physicians | HEPATOLOGY |
Resumen congreso | 2020 | The European NAFLD policy index - how well are countries prepared? | HEPATOLOGY |
Resumen congreso | 2020 | The impact of chronic hepatitis B on patient-reported outcomes from the global liver registry (TM) | HEPATOLOGY |
Resumen congreso | 2020 | The panppar agonist lanifibranor induces both resolution of NASH and regression of fibrosis after 24 weeks of treatment in non-cirrhotic NASH: results of the native phase 2b trial | HEPATOLOGY |
Resumen congreso | 2020 | The serum-based metabolomics advanced steatohepatits fibrosis score (MASEF) for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant fibrosis | HEPATOLOGY |
Resumen congreso | 2020 | Validation of a machine learning-based approach (delta liver fibrosis score) for the assessment of histologic response in patients with advanced fibrosis due to NASH | HEPATOLOGY |
Resumen congreso | 2019 | ACUTE ON CHRONIC LIVER FAILURE IS A MAJOR RISK FACTOR FOR BLEEDING CONTROL AND MORTALITY, WHILE PRE-EMPTIVE TIPS IMPROVES SURVIVAL IN THESE PATIENTS | HEPATOLOGY |
Resumen congreso | 2019 | CLINICAL AND PATIENT-REPORTED OUTCOMES (PROs) IN PATIENTS WITH CHRONIC HEPATITIS B VIRUS (HBV) INFECTION SEEN IN REAL-WORLD PRACTICES ACROSS THE WORLD: DATA FROM THE GLOBAL LIVER REGISTRY | HEPATOLOGY |
Resumen congreso | 2019 | CLINICAL AND PATIENT-REPORTED OUTCOMES DATA FOR PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND NON-ALCOHOLIC STEATOHEPATITIS (NASH) ACROSS THE WORLD: DATA FROM THE GLOBAL NASH REGISTRY | HEPATOLOGY |
Resumen congreso | 2019 | CURRENTLY AVAILABLE NONINVASIVE TESTS ACCURATELY STAGE FIBROSIS IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) | HEPATOLOGY |
Resumen congreso | 2019 | DESCRIPTION OF VIRAL HEPATITIS PATIENTS AND ASSOCIATED RISK FACTORS OF LATE PRESENTATION TO CARE IN SPAIN: A COUNTRY WITH UNRESTRICTED ACCESS TO TREATMENT | HEPATOLOGY |
Resumen congreso | 2019 | DIFFERENCES IN THE CLINICAL PROFILE OF THE MOST COMMON CAUSES OF CHRONIC LIVER DISEASE (CLD) ACROSS THE WORLD: DATA FROM THE GLOBAL LIVER REGISTRY. | HEPATOLOGY |
Resumen congreso | 2019 | Droplet digital pcr analysis of circulating lncrna h19: a potential biomarker for hepatocellular carcinoma | HEPATOLOGY |
Resumen congreso | 2019 | FACTORS PREDICTING SURVIVAL IN PATIENTS WITH 'NON-HIGH-RISK' ACUTE VARICEAL BLEEDING RECEIVING NSBB AND/OR EBL TO PREVENT RE-BLEEDING | HEPATOLOGY |
Resumen congreso | 2019 | HETEROGENEITY OF CIRCULATING TUMOR CELLS BASED ON ASIALOGLYCOPROTEIN RECEPTOR 1 (ASGPR1) EXPRESSION IN HEPATOCELLULAR CARCINOMA AS PROGNOSTIC TOOL | HEPATOLOGY |
Resumen congreso | 2019 | IDENTIFICATION OF SERUM METABOLITES AS DIAGNOSTIC BIOMARKERS FOR ADVANCED FIBROSIS DUE TO NONALCOHOLIC STEATOHEPATITIS (NASH) | HEPATOLOGY |
Resumen congreso | 2019 | INTRATUMORAL EXPRESSION OF PD-1/PD-L1 IMMUNE CHECKPOINT IN PATIENTS WITH HEPATOCELLULAR CARCINOMA | HEPATOLOGY |
Resumen congreso | 2019 | NONINVASIVE TESTS (NITS) MORE ACCURATELY CAPTURE SURROGATES OF CLINICAL RESPONSE THAN LIVER HISTOLOGY IN NASH PATIENTS WITH ADVANCED FIBROSIS | HEPATOLOGY |
Artículo | 2019 | Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials | HEPATOLOGY |
Resumen congreso | 2019 | OBESE PATIENTS CARRYING NAFLD-ASSOCIATED GENETIC VARIANTS PRESENT SPECIFIC SERUM AND LIVER LIPIDOMIC PROFILES: IDENTIFICATION OF A LIPIDOMIC SIGNATURE IN SERUM TO ESTIMATE THE LIVER FAT CONTENT | HEPATOLOGY |
Resumen congreso | 2019 | OBETICHOLIC ACID (OCA) IMPROVES NON-INVASIVE MARKERS OF FIBROSIS IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH): A SECONDARY ANALYSIS OF THE PHASE 3 REGENERATE STUDY | HEPATOLOGY |
Resumen congreso | 2019 | OXIDIZED-LDL AS A MARKER OF OXIDATIVE STRESS IS STRONGLY RELATED TO NASH IRRESPECTIVELY OF INSULIN RESISTANCE AND LIVER FIBROSIS | HEPATOLOGY |
Resumen congreso | 2019 | PATIENT-REPORTED OUTCOMES (PROs) IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) AND COMPENSATED CIRRHOSIS (CC): DATA FROM THE STELLAR-4 PHASE 3 CLINICAL TRIAL | HEPATOLOGY |
Artículo | 2019 | Preemptive-TIPS Improves Outcome in High-Risk Variceal Bleeding: An Observational Study | HEPATOLOGY |
Resumen congreso | 2019 | RACE DOES NOT AFFECT THE PERFORMANCE OF ROUTINELY AVAILABLE NONINVASIVE TESTS FOR THE DISCRIMINATION OF ADVANCED FIBROSIS DUE TO NONALCOHOLIC STEATOHEPATITIS (NASH) IN THE PHASE 3 STELLAR TRIALS OF SELONSERTIB | HEPATOLOGY |
Resumen congreso | 2019 | REVACCINATION AGAINST HEPATITIS B VIRUS WITH A SCHEDULE OF THREE DOUBLE-DOSES IS MORE EFFECTIVE THAN AN ISOLATED DOUBLE-DOSE BOOSTER VACCINATION IN CIRRHOTIC PATIENTS EVALUATED AS POTENTIAL CANDIDATES FOR LIVER TRANSPLANTATION | HEPATOLOGY |
Resumen congreso | 2019 | SAFETY AND EFFICACY OF SELONSERTIB FOR THE TREATMENT OF BRIDGING FIBROSIS OR COMPENSATED CIRRHOSIS DUE TO NONALCOHOLIC STEATOHEPATITIS (NASH): RESULTS OF THE PHASE 3 STELLAR STUDIES | HEPATOLOGY |
Artículo | 2019 | Serum Metabolites as Diagnostic Biomarkers for Cholangiocarcinoma, Hepatocellular Carcinoma, and Primary Sclerosing Cholangitis | HEPATOLOGY |
Resumen congreso | 2019 | SEVERE IMPAIRMENT OF PATIENT-REPORTED OUTCOMES (PROs) IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS (HCV) INFECTION SEEN IN REAL-WORLD PRACTICES ACROSS THE WORLD: DATA FROM THE GLOBAL LIVER REGISTRY | HEPATOLOGY |
Resumen congreso | 2019 | THE ECONOMIC COST AND HEALTH BURDEN OF NON ALCOHOLIC STEATOHEPATITIS IN THE EU5 COUNTRIES | HEPATOLOGY |
Artículo | 2019 | Thioesterase Superfamily Member 2 Promotes Hepatic VLDL Secretion by Channeling Fatty Acids Into Triglyceride Biosynthesis | HEPATOLOGY |
Resumen congreso | 2019 | UREA CYCLE ENZYMES DYSREGULATION IS LINKED TO A MORE AGGRESSIVE NAFLD PHENOTYPE. | HEPATOLOGY |
Resumen congreso | 2019 | VALIDATION OF HISTOLOGIC AND NONINVASIVE MEASURES OF FIBROSIS AS SURROGATE ENDPOINTS OF DISEASE PROGRESSION IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) | HEPATOLOGY |
Resumen congreso | 2019 | VISCOELASTICITY AND STIFFNESS RESPONSE (VSR) WAS MODULATED BY ADIPOKINES HOMEOSTASIS BEYOND OF HCV CLEARANCE. | HEPATOLOGY |
Resumen congreso | 2018 | Abide: A Novel Predictive Model of Liver Decompensation in Patients with Non-Alcoholic Fatty Liver Related Cirrhosis. | HEPATOLOGY |
Resumen congreso | 2018 | Advanced Fibrosis Based on Noninvasive Tests in Nonalcoholic Steatohepatitis (NASH) Is Associated with Impairment of Patient-Reported Outcomes | HEPATOLOGY |
Resumen congreso | 2018 | Algorithms Using Noninvasive Tests Can Accurately Identify Patients with Advanced Fibrosis Due to Nash: Data from the Stellar Clinical Trials | HEPATOLOGY |
Resumen congreso | 2018 | Burden and Variability in the Management of NAFLD Patients in Clinical Practice: Toward Unified Criteria. | HEPATOLOGY |
Resumen congreso | 2018 | Diabetes but Not Metabolic Syndrome Adversely Impact Survival or Liver Decompensation in Patients with Non-Alcoholic Fatty Liver Related Cirrhosis. | HEPATOLOGY |
Resumen congreso | 2018 | Dynamic of Microparticles in Patients with Hepatitis C Receiving Daa and Their Impact on Cardiovascular Risk: Hepcar Study | HEPATOLOGY |
Resumen congreso | 2018 | Extrahepatic Autoimmune Comorbidities in Patients with Primary Biliary Cholangitis. Lack of Association with Prognosis and Therapeutic Response to Ursodeoxycholic Acid. | HEPATOLOGY |
Resumen congreso | 2018 | Fibroblast Growth Factor 21 (FGF21) in NAFLD: From a Biomarker to a Therapeutic Target. | HEPATOLOGY |
Artículo | 2018 | Hepatology Highlights | HEPATOLOGY |
Resumen congreso | 2018 | Metabolically Healthy Obesity Is a Dynamic Condition Which Progress to Unhealthy Status According to Nash and Fibrosis Stage in Biopsy-Proven NAFLD Patients | HEPATOLOGY |
Resumen congreso | 2018 | New Automated Evaluation Tool Qfibs - Quantitative Assessment for Fibrosis, Inflammation, Ballooning, and Steatosis in Patients with Non-Alcoholic Steatohepatitis | HEPATOLOGY |
Resumen congreso | 2018 | Non-Alcoholic Fatty Liver Disease (NAFLD) and Alcoholic Fatty Liver Disease (AFLD): The Impact of Alcohol Consumption and Metabolic Syndrome on Mortality | HEPATOLOGY |
Resumen congreso | 2018 | Role of the Long Non-Coding RNA H19 in the Context of Hepatocellular Carcinoma | HEPATOLOGY |
Resumen congreso | 2018 | Routinely Available Noninvasive Tests Discriminate Advanced Fibrosis Due to Nash in the Phase 3 Stellar Trials of the ASK1 Inhibitor Selonsertib | HEPATOLOGY |
Resumen congreso | 2018 | Severe Impairment of Patient-Reported Outcomes in Patients with Advanced Fibrosis Due to Non-Alcoholic Steatohepatitis (NASH) | HEPATOLOGY |
Editorial | 2018 | Solving doubts about L-ornithine L-aspartate for overt hepatic encephalopathy: Whom and how to treat | HEPATOLOGY |
Resumen congreso | 2018 | Steatohepatitis and Fibrosis Influence the Occurrence of Type 2 Diabetes Mellitus during the Follow-up in Non-Diabetic Biopsy-Proven NAFLD Patients | HEPATOLOGY |
Resumen congreso | 2017 | Early emergence of opportunistic infections after starting direct acting antiviral drugs in HIV/HCV coinfected patients | HEPATOLOGY |
Resumen congreso | 2017 | Effectiveness And Safety Of Elbasvir/Grazoprevir Treatment For HCV Patients In Real-Life Clinical Practice: Results From Spanish Hepa-C Cohort | HEPATOLOGY |
Resumen congreso | 2017 | Everolimus allows a significant and safe reduction of tacrolimus exposure in the de novo liver transplantation recipients and improves kidney function: 52 weeks data from REDUCE study | HEPATOLOGY |
Resumen congreso | 2017 | The impact of age on phenotype presentation and severity in patients with idiosyncratic drug-induced liver injury (DILI) | HEPATOLOGY |
Resumen congreso | 2017 | The Long-Term Clinical Course of Histologically Advanced Nonalcoholic Fatty Liver Disease. Impact of Fibrosis Severity on Major Clinical Outcomes. | HEPATOLOGY |
Artículo | 2017 | Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa-C registry | HEPATOLOGY |
Resumen congreso | 2017 | Type 2 diabetes and anti-diabetic medications modify the risk of liver-related outcomes in subjects with non-alcoholic fatty liver disease and advanced fibrosis. Results of a multicenter international cohort study. | HEPATOLOGY |
Resumen congreso | 2016 | Advanced fibrosis is independently associated with impaired kidney function in biopsy-proven NAFLD. Results of a multicenter cross-sectional study | HEPATOLOGY |
Resumen congreso | 2016 | Charlson Comorbidity Index predicts the overall benefit of IFN-free therapy in hepatitis (HepCom Study) | HEPATOLOGY |
Resumen congreso | 2016 | Critical Flicker Frequency predicts progression among stages of cirrhosis | HEPATOLOGY |
Artículo | 2016 | Development and Validation of a Noninvasive Prediction Model for Nonalcoholic Steatohepatitis Resolution After Lifestyle Intervention | HEPATOLOGY |
Artículo | 2016 | Diverse Impacts of the rs58542926 E167K Variant in TM6SF2 on Viral and Metabolic Liver Disease Phenotypes | HEPATOLOGY |
Resumen congreso | 2016 | Early-TIPS improves survival in high-risk variceal bleeders. Results of a Multicenter Variceal Bleeding Observational Study | HEPATOLOGY |
Resumen congreso | 2016 | Eliminating Hepatitis C in Spain: Bridging from the National Health Plan | HEPATOLOGY |
Artículo | 2016 | Human immunodeficiency virus infection does not worsen prognosis of liver transplantation for hepatocellular carcinoma | HEPATOLOGY |
Letter | 2016 | Identifying Patients With Nonalcoholic Steatohepatitis That Are Nonresponders to Therapy Reply | HEPATOLOGY |
Resumen congreso | 2016 | Improvement of carotid intima-media thickness and ankle-brachial index in patients with hepatitis C virus after IFN-free treatment. | HEPATOLOGY |
Resumen congreso | 2016 | LNCRNA H19 Is Increased In Hepatocellular Carcinoma With Underlying Hcv-Related Cirrhosis | HEPATOLOGY |
Resumen congreso | 2016 | Oral glutamine challenge predicts and identifies long-term ammonia-related overt hepatic encephalopathy | HEPATOLOGY |
Resumen congreso | 2016 | SCCA-IgM helps to identify patients at risk of long-term hepatocelullar carcinoma | HEPATOLOGY |
Resumen congreso | 2016 | Sofosbuvir/Ledipasvir plus Ribavirin achieves high SVR12 in genotype-3 patients with compensated cirrhosis and similar to Sofosbuvir plus Daclatasvir. A multicentre real life cohort | HEPATOLOGY |
Resumen congreso | 2016 | Spanish Drug-Induced Liver Injury Registry: An update of 20-years prospective collection of idiosyncratic hepatotoxicity cases. | HEPATOLOGY |
Resumen congreso | 2015 | An international, phase 2 randomized controlled trial of the dual PPAR alpha-delta agonist GFT505 in adult patients with NASH | HEPATOLOGY |
Resumen congreso | 2015 | Beneficial effects of the dual PPAR alpha-delta agonist, GFT505, on hepatic and cardiometabolic markers in adult NASH patients. | HEPATOLOGY |
Resumen congreso | 2015 | Clinical features and risk factors associated with Non-alcoholic steatohepatitis (NASH) in Spain. On behalf of HEPAmet Registry | HEPATOLOGY |
Resumen congreso | 2015 | HCV genotype 3: Meta-analysis with current options | HEPATOLOGY |
Resumen congreso | 2015 | Impact of comorbidities on the benefit of DAA therapy in Hepatitis C | HEPATOLOGY |
Artículo | 2015 | Low risk of liver decompensation among human immunodeficiency virus/hepatitis C virus-coinfected patients with mild fibrosis in the short term | HEPATOLOGY |
Editorial | 2015 | Sofosbuvir Modulates the Intimate Relationship Between Hepatitis C Virus and Lipids | HEPATOLOGY |
Resumen congreso | 2015 | Substantial variability of the diagnostic accuracy of serum fibrosis markers across multiple cohorts of nash patients in various centers : the case for the negative predictive value | HEPATOLOGY |
Resumen congreso | 2015 | The hepatic and extra-hepatic profile of resolution of steatohepatitis induced by GFT-505 | HEPATOLOGY |
Resumen congreso | 2014 | Altered underlying tubular function in HBV monoinfected patients receiving nucleos(t)ide analogs in a real-world setting: MENTE Study | HEPATOLOGY |
Resumen congreso | 2014 | Bacterial antigen translocation in patients with cirrhosis and minimal hepatic encephalopathy is associated with increased serum ammonia and nitric oxide levels | HEPATOLOGY |
Resumen congreso | 2014 | Efficacy by Race or Geographic Region in HCV Genotype 1-infected Patients Treated with ABT-450/ritonavir/Ombitasvir and Dasabuvir With or Without Ribavirin | HEPATOLOGY |
Artículo | 2014 | GATA4 loss in the septum transversum mesenchyme promotes liver fibrosis in mice | HEPATOLOGY |
Resumen congreso | 2014 | Killer Ig-like receptors (KIR) profiles and HLA class I ligands in amoxicillin-clavulanate-induced hepatotoxicity | HEPATOLOGY |
Resumen congreso | 2014 | Metformin reduces hyperammonemia in portacaval shunted rats inhibiting intestinal glutaminase activity | HEPATOLOGY |
Resumen congreso | 2014 | Protease inhibitors impair renal function in HCV-infected immunocompetent patients | HEPATOLOGY |
Resumen congreso | 2014 | Quercetin inhibits both replication and assembly of hepatitis C virus by blocking the viral NS3 and the host diacylglycerol acyltransferase type 1 | HEPATOLOGY |
Resumen congreso | 2014 | Risk factors for chronicity in idiosyncratic drug-induced liver injury (DILI) | HEPATOLOGY |
Resumen congreso | 2014 | Statins and metformin use improve prognosis after diagnosis of hepatocelullar carcinoma | HEPATOLOGY |
Resumen congreso | 2014 | Statins interfere on TCTP and PI3K/AKT/mTOR pathway and inhibit hepatocellular carcinoma progression | HEPATOLOGY |
Resumen congreso | 2013 | Cost-saving approach to triple therapy for hepatitis C using the OPTIM prognostic tool to predict virologic response to 4 weeks of peginterferon and ribavirin in genotype 1 patients | HEPATOLOGY |
Ponencia | 2013 | Efficacy and safety of triple therapy with Peginterferon, Ribavirin, and Boceprevir within Early Access Program in Spanish patients with hepatitis c genotype 1 with severe fibrosis. SVRw12 Analisys | HEPATOLOGY |
Resumen congreso | 2013 | Genetic variants of the Niemann-Pick C1-like 1 cholesterol absorption receptor and response to antiviral therapy in HCV patients | HEPATOLOGY |
Resumen congreso | 2013 | Increased circulating soluble CD36 is associated with advanced steatosis in patients with nonalcoholic fatty liver disease | HEPATOLOGY |
Resumen congreso | 2013 | Influence of PNPLA3 genotypes on histological features and adiponutrin serum levels in patients with NAFLD | HEPATOLOGY |
Editorial | 2013 | Insulin Resistance, Telaprevir, and Virological Response in Hepatitis C: The Debate Must Go On | HEPATOLOGY |
Ponencia | 2013 | KLF12 polymorphism improves ITPA predictability of anemia in hepatitis C treated with peginterferon plus ribavirin | HEPATOLOGY |
Ponencia | 2013 | Metformin reduces plasmatic ammonia in portacaval shunted rats | HEPATOLOGY |
Artículo | 2013 | PROPEL: A randomized trial of mericitabine plus peginterferon alpha-2a/ribavirin therapy in treatment-naive HCV genotype 1/4 patients | HEPATOLOGY |
Resumen congreso | 2013 | Quercetin inhibits HCV replication by modulating lipid droplets morphology and core protein co-localization | HEPATOLOGY |
Resumen congreso | 2013 | Serum levels of PNPLA3 are related to the development of steatohepatitis in non alcoholic fatty liver disease patients | HEPATOLOGY |
Ponencia | 2013 | Usefulness in clinical practice of NASHMRi for the detection of steatohepatitis in patients with NAFLD | HEPATOLOGY |
Resumen congreso | 2013 | Validation study of the impact of SNPs from GWAS associated with fibrosis progression in chronic hepatitis C (HCV) | HEPATOLOGY |
Ponencia | 2012 | Anti-LDL-oxidized antibodies: a link between NASH and cardiovascular disease | HEPATOLOGY |
Ponencia | 2012 | Determination of the presence of Steatohepatitis in Non-Alcoholic Fatty Liver disease based on optical analysis of Liver MRI and artificial neural networks (FibroMRi) | HEPATOLOGY |
Ponencia | 2012 | Early virological dynamics on genotype 1 & 4 coinfected (HCV/HIV) and monoinfected (HCV) patients treated with peginterferon-alpha 2a plus ribavirin. An interim analysis of the OPTIM study | HEPATOLOGY |
Resumen congreso | 2012 | Efficacy and safety of aggressive antiviral treatment for recurrent hepatitis C after liver transplantation. Influence of Receptor and Donor Interleukin 28B Polymorfisms in virological response | HEPATOLOGY |
Ponencia | 2012 | Genome-Wide Association Analysis Confirms Importance of PNPLA3 and Identifies Novel Variants Associated With Histologically Progressive Steatohepatitis in NAFLD | HEPATOLOGY |
Artículo | 2012 | Hepatic steatosis and steatohepatitis in human immunodeficiency virus/hepatitis C virus-coinfected patients | HEPATOLOGY |
Ponencia | 2012 | HLA class I and II alleles influence the amoxicillin-clavulanate hepatotoxicity signature | HEPATOLOGY |
Ponencia | 2012 | IL28B-based model for prediction of early response in patients with hepatitis C genotype 1&4 treated with peginterferon alfa 2a plus ribavirin (P plus R). OPTIM study | HEPATOLOGY |
Ponencia | 2012 | Influence of IL-28B genotype on efficacy of retreatment with pegifn alfa-2A and ribavirin in patients with chc and failure of previous treatment (agora study): results at week 12 | HEPATOLOGY |
Ponencia | 2012 | Interaction between host and viral genotypes influenced hepatitis C infection | HEPATOLOGY |
Artículo | 2012 | Liver stiffness predicts clinical outcome in human immunodeficiency virus/hepatitis C virus-coinfected patients with compensated liver cirrhosis | HEPATOLOGY |
Ponencia | 2012 | miRNAs involved in insulin resistance are regulated in vitro by HCV infection | HEPATOLOGY |
Ponencia | 2012 | Non-alcoholic fatty liver disease (NAFLD) influences on cardiovascular disease: Meta-analysis | HEPATOLOGY |
Ponencia | 2012 | PNPLA3 and DISC1 are associated with steatosis in patients with chronic hepatitis C | HEPATOLOGY |
Ponencia | 2012 | Retreatment of patients with Hepatitis C and failure of previous treatment with peg-ifn and RBV (agora study): results at week 12 | HEPATOLOGY |
Ponencia | 2012 | Utility of agora criteria in the decision to re-treat patients with Hepatitis C and failure of previous treatment with peg-ifn and RBV | HEPATOLOGY |
Ponencia | 2012 | Validation of FibroMax and NAFLDscore in a cohort of NAFLD Spanish patients | HEPATOLOGY |
Ponencia | 2012 | Vitamin D supplementation influences sustained virological response rate in Hepatitis C: a systematic review and meta-analysis | HEPATOLOGY |
Ponencia | 2011 | CHEMORESISTANCE CAN BE INDUCED BY BILE ACID-INDEPENDENT ACTIVATION OF FXR IN LIVER AND INTESTINAL CANCER CELLS | HEPATOLOGY |
Ponencia | 2011 | CONNECTIVE TISSUE GROWTH FACTOR AUTOCRINY IN HEPATOCELLULAR CARCINOMA: ONCOGENIC ROLE AND REGULATION BY EGFR/YAP-MEDIATED ACTIVATION | HEPATOLOGY |
Artículo | 2011 | Connective tissue growth factor autocriny in human hepatocellular carcinoma: Oncogenic role and regulation by epidermal growth factor receptor/yes-associated protein-mediated activation | HEPATOLOGY |
Ponencia | 2011 | HCVAC STUDY: ANTIVIRAL ACTIVITY OF TG4040 THERAPEUTIC VACCINE IN GENOTYPE-1 CHRONIC HCV PATIENTS | HEPATOLOGY |
Ponencia | 2011 | HOMA1-IR AND HOMA2-IR INDEXES IN IDENTIFYING INSULIN RESISTANCE IN CHRONIC HEPATITIS C | HEPATOLOGY |
Ponencia | 2011 | INSULIN RESISTANCE PREDICTS SUSTAINED VIROLOGICAL RESPONSE INDEPENDENTLY TO IL28B RS12979860 POLYMORPHISM IN TREATED PATIENTS WITH CHRONIC HEPATITIS C | HEPATOLOGY |
Ponencia | 2011 | INSULIN SENSITIZER USE WAS ASSOCIATED WITH LOWER RATE OF CIRRHOSIS OUTCOMES: HEPATIC ENCEPHALOPATHY AND SPONTANEOUS BACTERIAL PERITONITIS | HEPATOLOGY |
Artículo | 2011 | Linkage of the Hepatitis C Virus Genotype and Interleukin-28B Genetic Polymorphisms in Asian Patients Reply | HEPATOLOGY |
Letter | 2011 | Linkage of the Hepatitis C Virus Genotype and Interleukin-28B Genetic Polymorphisms in Asian Patients Reply | HEPATOLOGY |
Ponencia | 2011 | METFORMIN AND RAPAMYCIN INTERACT WITH INSULIN SIGNALLING PATHWAY AND INHIBIT HCV REPLICATION IN VITRO | HEPATOLOGY |
Ponencia | 2011 | NONINVASIVE ASSESSMENT OF LIVER FIBROSIS BY FORNS INDEX IS A PREDICTIVE FACTOR OF RESPONSE SIMILAR TO HISTOLOGICAL FIBROSIS IN PATIENTS WITH HEPATITIS C | HEPATOLOGY |
Resumen congreso | 2011 | Obesity dependent metabolic signatures associated with nonalcoholic fatty liver disease progression | HEPATOLOGY |
Ponencia | 2011 | PROTEOMIC ANALYSIS OF HEPATITIS C INFECTION IN AN IN VITRO MODEL REVEALS A POTENTIAL NEW THERAPEUTIC TARGET: TCTP (TRANSCRIPTION CONTROLLED TUMOR PROTEIN) | HEPATOLOGY |
Ponencia | 2011 | THE ROLE OF THE ABCB1 2677G > T,A POLYMORPHISM IN BILIRUBIN SUBSTRATE SPECIFICITY IN DRUG-INDUCED LIVER INJURY (DILI) | HEPATOLOGY |
Resumen congreso | 2010 | CHARACTERISTICS OF HEPATOPULMONARY SYNDROME IN CIRRHOTIC PATIENTS UNDER EVALUATION FOR LIVER TRANSPLANTATION | HEPATOLOGY |
Artículo | 2010 | Expression of Pituitary Tumor-Transforming Gene 1 (PTTG1)/Securin in Hepatitis B Virus (HBV)-Associated Liver Diseases: Evidence for an HBV X Protein-Mediated Inhibition of PTTG1 Ubiquitination and Degradation | HEPATOLOGY |
Resumen congreso | 2010 | IL28B POLYMORPHISM PREDICTS SUSTAINED VIROLOGICAL RESPONSE IN HEPATITIS C BUT IS NOT ASSOCIATED WITH FIBROSIS OR VIRAL LOAD | HEPATOLOGY |
Resumen congreso | 2010 | IL28B RS12979860 SNP is associated with lipids metabolism, viral genotype and spontaneous viral clearance in hepatitis C | HEPATOLOGY |
Ponencia | 2010 | IMPORTANCE OF HOST GENETIC FACTOR, HLA AND IL28B, AS PREDICTORS OF RESPONSE TO PEGYLATED INTERFERON AND RIBAVIRIN IN PATIENTS WITH CHRONIC HEPATITIS C | HEPATOLOGY |
Ponencia | 2010 | INADECUATE COMPENSATION BY GLUTAMINE SYNTHETASE AND INCREASED GLUTAMINASE ACTIVITY CONTRIBUTES TO HYPERAMMONAEMIA IN CIRRHOSIS | HEPATOLOGY |
Artículo | 2010 | Inhibition of poly adenosine diphosphate-ribose polymerase decreases hepatocellular carcinoma growth by modulation of tumor-related gene expression | HEPATOLOGY |
Resumen congreso | 2010 | Insulin signalling can be blocked in huh7.5 cells transfected with jfh1 by ptpb1 over-expression | HEPATOLOGY |
Ponencia | 2010 | Interaction between chemical structures and genetic variability in the hepatocellular transporter bile salt export pump (bsep) as a susceptibility factor to idiosyncratic drug-induced liver injury (dili) | HEPATOLOGY |
Artículo | 2010 | Interleukin-28B Genetic Variants and Hepatitis Virus Infection by Different Viral Genotypes | HEPATOLOGY |
Letter | 2010 | Metformin Improves Sustained Virologic Response in Difficult-to-Cure Hepatitis C: More Questions than Answers Reply | HEPATOLOGY |
Artículo | 2010 | Mitochondrial Superoxide Dismutase and Glutathione Peroxidase in Idiosyncratic Drug-Induced Liver Injury | HEPATOLOGY |
Letter | 2010 | Observed and Calculated Interleukin-28B Genotype Frequencies in Hepatitis C Virus Infection Reply | HEPATOLOGY |
Ponencia | 2010 | Optical analysis of liver magnetic resonance images for the determination of the stage and distribution of fibrosis in non-alcoholic fatty liver disease | HEPATOLOGY |
Resumen congreso | 2010 | PREVALENCE AND SEVERITY OF HEPATOPULMONARY SYNDROME IN CIRRHOTIC PATIENTS UNDER EVALUATION FOR LIVER TRANSPLANTATION. INFLUENCE ON SURVIVAL AND OUTCOME AFTER TRANSPLANT | HEPATOLOGY |
Ponencia | 2010 | THE MECHANISM BEHIND SYNERGISTIC ACTION OF LORNITHINE AND PHENYLACETATE TO REDUCE AMMONIA IN CIRRHOTIC RATS | HEPATOLOGY |
Ponencia | 2010 | WOULD IT BE DESIRABLE TO MODIFY THE CUT-OFF POINT FOR DEFINITION OF CHRONICITY IN DRUG-INDUCED LIVER INJURY (DILI)? | HEPATOLOGY |
Ponencia | 2010 | Would it be desirable to modify the cutoff point in the definition of chronicity in drug-induced liver injury (DILI)? | HEPATOLOGY |
Ponencia | 2009 | A MICROSATELLITE IN THE PROMOTER REGION OF THE GLS GENE PREDICTS THE RISK OF HEPATIC ENCEPHALOPATHY: FUNCTIONAL ANALYSIS USING LUCIFERASE REPORTER | HEPATOLOGY |
Ponencia | 2009 | Analisis of causes of response failure in naive patients with chronic hepatitis C receiving peginterferon plus rivavirin | HEPATOLOGY |
Artículo | 2009 | Fast Fibrosis Progression Between Repeated Liver Biopsies in Patients Coinfected with Human Immunodeficiency Virus/Hepatitis C Virus | HEPATOLOGY |
Corrección | 2009 | Glutathione S-Transferase M1 and T1 Null Genotypes Increase Susceptibility to Idiosyncratic Drug-Induced Liver Injury (vol 48, pg 588, 2008) | HEPATOLOGY |
Letter | 2009 | Metformin, Hepatitis C, and Insulin Resistance: Sufficient Evidence? Reply | HEPATOLOGY |
Artículo | 2009 | Phenotypic Characterization of Idiosyncratic Drug-Induced Liver Injury: The Influence of Age and Sex | HEPATOLOGY |
Ponencia | 2009 | PREDICTIVE FACTORS OF SUSTAINED VIROLOGICAL RESPONSE IN PATIENTS WITH COMPLETE EARLY VIROLOGICAL RESPONSE TO THE TREATMENT OF HEPATITIS C | HEPATOLOGY |
Ponencia | 2009 | RELEVANCE OF MANGANESE SUPEROXIDE DISMUTASE (SOD2 VAL16ALA) AND GLUTATHIONE PEROXIDASE1 (GPX1 PRO198LEU) FUNCTIONAL POLYMORPHISMS IN PATIENTS WITH IDIOSYNCRATIC DRUG-INDUCED LIVER INJURY (DILI) | HEPATOLOGY |
Ponencia | 2009 | Thalidomide with peginterferon alfa-2b and ribavirin in the treatment of non-responders genotype 1 chronic hepatitis c patients (trital): proof of concept | HEPATOLOGY |
Ponencia | 2009 | The combined use of fibroct and forns index improves the non-invasive diagnosis of significant liver fibrosis in hepatitis C | HEPATOLOGY |
Ponencia | 2009 | THE NOS-3 OVEREXPRESSION INDUCES AN ENHANCED SUSCEPTIBILITY TO FAS-INDUCED CELL DEATH IN HEPATOMA CELL LINE | HEPATOLOGY |
Artículo | 2009 | Treatment of Insulin Resistance with Metformin in Naive Genotype 1 Chronic Hepatitis C Patients Receiving Peginterferon Alfa-2a Plus Ribavirin | HEPATOLOGY |
Ponencia | 2008 | EFFECT OF SUSTAINED VIROLOGICAL RESPONSE TO PEGINTERFERON PLUS RIBAVIRIN THERAPY ON LIVER RELATED FREE SURVIVAL IN HCV CIRRHOTIC PATIENTS. FACTORS PREDICTING VIROLOGICAL RESPONSE | HEPATOLOGY |
Artículo | 2008 | Glutathione s-transferase M1 and T1 null genotypes increase susceptibility to idiosyncratic drug-induced liver injury | HEPATOLOGY |
Ponencia | 2008 | INSULIN RESISTANCE CORRELATES WITH HVPG AND PREDICTS RISK FOR THE DEVELOPMENT OF VARICEAL BLEEDING IN CIRRHOTICS | HEPATOLOGY |
Resumen congreso | 2008 | INSULIN RESISTANCE CORRELATES WITH HVPG AND PREDICTS RISK FOR THE DEVELOPMENT OF VARICEAL BLEEDING IN CIRRHOTICS | HEPATOLOGY |
Ponencia | 2008 | METFORMIN WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN THE TREATMENT OF NAIVE GENOTYPE 1 CHRONIC HEPATITIS C PATIENTS WITH INSULIN RESISTANCE (TRIC-1): FINAL RESULTS OF A RANDOMIZED AND DOUBLE-BLINDED TRIAL | HEPATOLOGY |
Artículo | 2008 | Optical analysis of computed tomography images of the liver predicts fibrosis stage and distribution in chronic hepatitis C | HEPATOLOGY |
Ponencia | 2008 | POLYMORPHIC BILE SALT EXPORT PUMP TRANSPORTER IS A MAJOR DETERMINANT OF HEPATOCELLULAR DRUG-INDUCED LIVER INJURY | HEPATOLOGY |
Artículo | 2007 | Clinical progression of hepatitis C virus - Related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active Antiretroviral therapy | HEPATOLOGY |
Ponencia | 2007 | Genetic, polymorphisms of Il-10, Il-4 and TNF alpha and susceptibility to develop drug-induced idiosyncratic liver injury (DILI) | HEPATOLOGY |
Artículo | 2007 | Value of the critical flicker frequency in patients with minimal hepatic encephalopathy | HEPATOLOGY |
Artículo | 2006 | Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity: A prospective series from Spain | HEPATOLOGY |
Artículo | 2006 | Development and validation of two models for early prediction of response to therapy in genotype 1 chronic hepatitis C | HEPATOLOGY |
Ponencia | 2006 | Effect of sustained response in the incidence of type 2 diabetes mellitus in chronic hepatitis C | HEPATOLOGY |
Artículo | 2006 | Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry | HEPATOLOGY |
Ponencia | 2006 | Phosphate-activated glutaminase gene polymorphisms are implied in cirrhosis susceptibility and risk for hepatic encephalopathy | HEPATOLOGY |
Letter | 2005 | Antiretroviral therapy and liver fibrosis in HIV-infected patients with chronic hepatitis C | HEPATOLOGY |
Ponencia | 2005 | Are there differences in sustained virological response (SVR)rates in patients with HCV genotype 2 or 3 infection and persistently 'normal' ALT activity undergoing treatment with peginterferon alfa-2a (40KD) (PEGASYS (R)) plus ribavirin (COPEGUS (R))? | HEPATOLOGY |
Artículo | 2005 | HIV coinfection shortens the survival of patients with hepatitis c virus-related decompensated cirrhosis | HEPATOLOGY |
Letter | 2005 | HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis [2] (multiple letters) | HEPATOLOGY |
Ponencia | 2005 | N-acetilcysteine enhances toxin-induced cell death in primary culture of human hepatocytes | HEPATOLOGY |
Artículo | 2004 | HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease | HEPATOLOGY |
Ponencia | 2004 | Increased phosphate-activated glutaminase activity contributes substantially to the hyperammonemia in acute liver failure. | HEPATOLOGY |
Ponencia | 2004 | Longer treatment duration with peginterferon alfa-2A (40kd) (Pegasys (R)) and ribavirin (Copegus (R)) in naive patients with chronic hepatitis C and detectable HCV RNA by week 4 of therapy: Final results of the randomized, multicenter TeraViC-4 study | HEPATOLOGY |
Ponencia | 2004 | Peginterferon alfa-2a (40KD) (Pegasys (R)) and ribavirin (Copegus (R)) in patients infected with HCV genotype 1 who failed to respond to interferon and ribavirin: Final results of the Spanish High-Dose Induction Pilot Trial. | HEPATOLOGY |
Artículo | 2004 | PGE(1)-induced NO reduces apoptosis by D-galactosamine through attenuation of NF-kappa B and NOS-2 expression in rat hepatocytes | HEPATOLOGY |
Artículo | 2004 | Prognostic value of altered oral glutamine challenge in patients with minimal hepatic encephalopathy | HEPATOLOGY |
Ponencia | 2003 | Computer-performed optical analysis of conventional helical CT of the liver could predict liver fibrosis staging in patients with chronic hepatitis C. | HEPATOLOGY |
Ponencia | 2003 | High-dose peginterferon alfa-2a (40KD) (PEGASYS (R)) and ribavirin (COPEGUS (R)) in patients infected with hepatitis C virus (HCV) genotype 1 who failed to respond to interferon alfa and ribavirin. | HEPATOLOGY |
Resumen congreso | 2003 | Insulin resistance impairs sustained response rate to antiviral therapy in patients with chronic hepatitis C. | HEPATOLOGY |
Ponencia | 2003 | Longer treatment duration with peginterferon alfa-2a (40KD) (PEGASYS (R)) and ribavirin (COPEGUS (R)) in naive patients with chronic hepatitis C and detectable HCV RNA by week 4 of therapy: Preliminary results of the TeraVIC-4 study. | HEPATOLOGY |
Resumen congreso | 2002 | Role of CCR2-V64I and CCR5 Delta 32 polymorphisms in the histological damage and progression rate of hepatitis C virus infection. | HEPATOLOGY |
Ponencia | 2002 | Role of nitric oxide on the induction of cell death by D-galactosamine and its protection by PGE(1) in primary culture of rat hepatocytes. | HEPATOLOGY |
Ponencia | 2001 | Role of TNF-alpha on the apoptosis and necrosis induced by D-galactosamine in primary culture of rat hepatocytes or in co-culture with rat Kupffer cells. Protective effect of PGE(1) on the apoptotic cell death pathway. | HEPATOLOGY |
Letter | 2000 | Acute hepatitis after starting zinc therapy in a patient with presymptomatic Wilson's disease | HEPATOLOGY |
Ponencia | 2000 | PGE(1) protection against D-galactosamine-induced apoptosis is through NF-KB activation | HEPATOLOGY |
Artículo | 1999 | Clinical and histological outcome after hepatitis B e antigen to antibody seroconversion in children with chronic hepatitis B | HEPATOLOGY |
Ponencia | 1999 | HLA class-II antigens in chronic hepatitis C: Relationship with interferon response and severity of liver disease. | HEPATOLOGY |
Ponencia | 1999 | Results of a nine year prospective protocol for early detection of de novo tumors after liver transplantation | HEPATOLOGY |
Ponencia | 1999 | Role of oxidative stress and caspase-1, -3 and -6 activation on D-galactosamine-induced apoptosis and its protection by PGE1 in primary culture of rat hepatocytes | HEPATOLOGY |
Ponencia | 1998 | Is subclinical hepatic encephalopathy a condition for further episodes of overt hepatic encephalopathy? | HEPATOLOGY |
Ponencia | 1998 | Long-term follow-up of patients with chronic hepatitis C and sustained response to interferon therapy. | HEPATOLOGY |
Artículo | 1998 | Pancreastatin receptor is coupled to a guanosine triphosphate-binding protein of the G(q/11)alpha family in rat liver membranes | HEPATOLOGY |
Ponencia | 1998 | Thioredoxin and glutaredoxin as markers of graft rejection after liver transplantation. | HEPATOLOGY |
Ponencia | 1998 | TNF-alpha-dependent production of inducible nitric oxide is involved in PGE(1) protection against acute liver injury. | HEPATOLOGY |
Artículo | 1997 | Detection of hepatitis GB virus type C RNA in serum and liver from children with chronic viral hepatitis B and C | HEPATOLOGY |
Ponencia | 1997 | Effect of PGE(1) and PGE(2) on apoptosis and cell cycle modifications induced with ethanol on primary culture of rat hepatocytes | HEPATOLOGY |
Ponencia | 1996 | Ameliorating the acceptance of liver grafts donors | HEPATOLOGY |
Ponencia | 1996 | Modification of Kupffer cells activation by different preservation solutions | HEPATOLOGY |
Artículo | 1995 | 2 DIFFERENT DOSAGES OF CEFOTAXIME IN THE TREATMENT OF SPONTANEOUS BACTERIAL PERITONITIS IN CIRRHOSIS - RESULTS OF A PROSPECTIVE, RANDOMIZED, MULTICENTER STUDY | HEPATOLOGY |
Ponencia | 1995 | APOPTOSIS IN EXPERIMENTAL HEPATITIS | HEPATOLOGY |
Artículo | 1995 | Differential effects of cytokines on the inducible expression of cyp1a1, CYP1A2, and CYP3A4 in human hepatocytes in primary culture | HEPATOLOGY |
Artículo | 1995 | DIFFERENTIAL-EFFECTS OF CYTOKINES ON THE INDUCIBLE EXPRESSION OF CYP1A1, CYP1A2, AND CYP3A4 IN HUMAN HEPATOCYTES IN PRIMARY CULTURE | HEPATOLOGY |
Ponencia | 1995 | Hepatitis-C virus genotypes in serum and liver of children with chronic hepatitis-C | HEPATOLOGY |
Ponencia | 1994 | HCV genotypes in children and response to interferon therapy | HEPATOLOGY |
Artículo | 1990 | NORFLOXACIN PREVENTS SPONTANEOUS BACTERIAL PERITONITIS RECURRENCE IN CIRRHOSIS - RESULTS OF A DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL | HEPATOLOGY |